VERTEX PHARMACEUTICALS INC / MA Restructuring Reserve, Period Increase (Decrease)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Restructuring Reserve, Period Increase (Decrease) of -$5.99 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-15.
Discontinued › Notes › Restructuring and Related Activities
us-gaap:RestructuringReservePeriodIncreaseDecrease · last filed 2018-02-15
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, period increase (decrease) for the quarter ending 2017-12-31 was -$2.12M, a 392.97% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, period increase (decrease) for the quarter ending 2017-09-30 was -$2.81M.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, period increase (decrease) for the quarter ending 2017-06-30 was -$1.36M.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, period increase (decrease) for the quarter ending 2017-03-31 was $305.00K.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, period increase (decrease) for fiscal 2017 was -$5.99M.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, period increase (decrease) for fiscal 2016 was -$7.43M.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, period increase (decrease) for fiscal 2015 was -$30.49M, a 274.22% decline from fiscal 2014.
- VERTEX PHARMACEUTICALS INC / MA restructuring reserve, period increase (decrease) for fiscal 2014 was $17.50M, a 248.30% increase from fiscal 2013.
| Period end | Restructuring Reserve, Period Increase (Decrease) 3 month | Restructuring Reserve, Period Increase (Decrease) 6 month | Restructuring Reserve, Period Increase (Decrease) 9 month | Restructuring Reserve, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$4.93M derived: sum of 2 quarters · filed 2018-02-15 | -$6.29M derived: sum of 3 quarters · filed 2018-02-15 | -$5.99M 10-K · filed 2018-02-15 |
| 2017-09-30 | -$2.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | -$4.17M derived: sum of 2 quarters · filed 2017-10-30 | -$3.86M 10-Q · filed 2017-10-30 | -$3.14M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-06-30 | -$1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | -$1.06M 10-Q · filed 2017-07-28 | -$333.00K derived: sum of 3 quarters · filed 2018-02-15 | -$5.59M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-03-31 | $305.00K 10-Q · filed 2017-04-28 | $1.03M derived: sum of 2 quarters · filed 2018-02-15 | -$4.23M derived: sum of 3 quarters · filed 2018-02-15 | -$5.66M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-12-31 | $725.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$4.53M derived: sum of 2 quarters · filed 2018-02-15 | -$5.97M derived: sum of 3 quarters · filed 2018-02-15 | -$7.43M 10-K · filed 2018-02-15 |
| 2016-09-30 | -$5.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | -$6.69M derived: sum of 2 quarters · filed 2017-10-30 | -$8.15M 10-Q · filed 2017-10-30 | -$10.59M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | -$1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | -$2.89M 10-Q · filed 2017-07-28 | -$5.33M derived: sum of 3 quarters · filed 2018-02-15 | -$7.37M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | -$1.46M 10-Q · filed 2017-04-28 | -$3.90M derived: sum of 2 quarters · filed 2018-02-15 | -$5.94M derived: sum of 3 quarters · filed 2018-02-15 | -$7.58M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | -$2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$4.48M derived: sum of 2 quarters · filed 2018-02-15 | -$6.13M derived: sum of 3 quarters · filed 2018-02-15 | -$30.49M 10-K · filed 2018-02-15 |
| 2015-09-30 | -$2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | -$3.68M derived: sum of 2 quarters · filed 2016-10-31 | -$28.05M 10-Q · filed 2016-10-31 | -$37.80M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | -$1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | -$26.01M 10-Q · filed 2016-08-01 | -$35.76M derived: sum of 3 quarters · filed 2017-02-23 | $859.00K derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | -$24.37M 10-Q · filed 2016-05-03 | -$34.11M derived: sum of 2 quarters · filed 2017-02-23 | $2.50M derived: sum of 3 quarters · filed 2017-02-23 | -$2.38M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | -$9.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $26.87M derived: sum of 2 quarters · filed 2017-02-23 | $21.99M derived: sum of 3 quarters · filed 2017-02-23 | $17.50M 10-K · filed 2017-02-23 |
| 2014-09-30 | $36.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | $31.73M derived: sum of 2 quarters · filed 2015-10-30 | $27.25M 10-Q · filed 2015-10-30 | $29.46M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | -$4.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | -$9.37M 10-Q · filed 2015-08-04 | -$7.15M derived: sum of 3 quarters · filed 2016-02-16 | -$3.07M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-03-31 | -$4.49M 10-Q · filed 2015-05-04 | -$2.27M derived: sum of 2 quarters · filed 2016-02-16 | $1.81M derived: sum of 3 quarters · filed 2016-02-16 | $1.41M derived: sum of 4 quarters · filed 2016-02-16 |
| 2013-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $6.30M derived: sum of 2 quarters · filed 2016-02-16 | $5.89M derived: sum of 3 quarters · filed 2016-02-16 | $5.03M 10-K · filed 2016-02-16 |
| 2013-09-30 | $4.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $3.68M derived: sum of 2 quarters · filed 2014-11-06 | $2.81M 10-Q · filed 2014-11-06 | $1.98M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | -$407.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | -$1.28M 10-Q · filed 2014-07-31 | -$2.10M derived: sum of 3 quarters · filed 2015-02-13 | -$2.78M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | -$869.00K 10-Q · filed 2014-05-05 | -$1.70M derived: sum of 2 quarters · filed 2015-02-13 | -$2.37M derived: sum of 3 quarters · filed 2015-02-13 | -$3.01M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | -$827.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$1.50M derived: sum of 2 quarters · filed 2015-02-13 | -$2.15M derived: sum of 3 quarters · filed 2015-02-13 | -$2.98M 10-K · filed 2015-02-13 |
| 2012-09-30 | -$675.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$1.32M derived: sum of 2 quarters · filed 2013-11-07 | -$2.16M 10-Q · filed 2013-11-07 | -$2.43M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | -$643.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | -$1.48M 10-Q · filed 2013-08-02 | -$1.75M derived: sum of 3 quarters · filed 2014-02-11 | -$3.38M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | -$840.00K 10-Q · filed 2013-05-08 | -$1.11M derived: sum of 2 quarters · filed 2014-02-11 | -$2.73M derived: sum of 3 quarters · filed 2014-02-11 | -$3.34M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | -$271.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | -$1.89M derived: sum of 2 quarters · filed 2014-02-11 | -$2.50M derived: sum of 3 quarters · filed 2014-02-11 | -$3.28M 10-K · filed 2014-02-11 |
| 2011-09-30 | -$1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | -$2.23M derived: sum of 2 quarters · filed 2012-11-06 | -$3.01M 10-Q · filed 2012-11-06 | -$6.65M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | -$609.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | -$1.39M 10-Q · filed 2012-08-08 | -$5.03M derived: sum of 3 quarters · filed 2013-03-01 | -$5.72M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | -$781.00K 10-Q · filed 2012-05-10 | -$4.42M derived: sum of 2 quarters · filed 2013-03-01 | -$5.11M derived: sum of 3 quarters · filed 2013-03-01 | -$4.52M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | -$3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | -$4.33M derived: sum of 2 quarters · filed 2013-03-01 | -$3.74M derived: sum of 3 quarters · filed 2013-03-01 | -$4.42M 10-K · filed 2013-03-01 |
| 2010-09-30 | -$686.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$95.00K derived: sum of 2 quarters · filed 2011-11-03 | -$779.00K 10-Q · filed 2011-11-03 | -$120.00K derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-06-30 | $591.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | -$93.00K 10-Q · filed 2011-08-09 | $566.00K derived: sum of 3 quarters · filed 2012-02-22 | -$126.00K derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-03-31 | -$684.00K 10-Q · filed 2011-05-06 | -$25.00K derived: sum of 2 quarters · filed 2012-02-22 | -$717.00K derived: sum of 3 quarters · filed 2012-02-22 | -$1.48M derived: sum of 4 quarters · filed 2012-02-22 |
| 2009-12-31 | $659.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | -$33.00K derived: sum of 2 quarters · filed 2012-02-22 | -$794.00K derived: sum of 3 quarters · filed 2012-02-22 | -$47.00K 10-K · filed 2012-02-22 |
| 2009-09-30 | -$692.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | -$1.45M derived: sum of 2 quarters · filed 2010-10-28 | -$706.00K 10-Q · filed 2010-10-28 | |
| 2009-06-30 | -$761.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-03 | -$14.00K 10-Q · filed 2010-08-03 | ||
| 2009-03-31 | $747.00K 10-Q · filed 2010-05-03 | |||
| 2008-12-31 | -$1.23M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |